[go: up one dir, main page]

ECSP10010665A - Formulaciones orales de análogos de citidina y métodos para usar los mismos - Google Patents

Formulaciones orales de análogos de citidina y métodos para usar los mismos

Info

Publication number
ECSP10010665A
ECSP10010665A EC2010010665A ECSP10010665A ECSP10010665A EC SP10010665 A ECSP10010665 A EC SP10010665A EC 2010010665 A EC2010010665 A EC 2010010665A EC SP10010665 A ECSP10010665 A EC SP10010665A EC SP10010665 A ECSP10010665 A EC SP10010665A
Authority
EC
Ecuador
Prior art keywords
methods
oral formulations
same
citidine
analogs
Prior art date
Application number
EC2010010665A
Other languages
English (en)
Inventor
Jeffrey W Etter
Mel Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010665(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ECSP10010665A publication Critical patent/ECSP10010665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción provee composiciones farmacéuticas que comprenden análogos de citidina para administración oral en donde las composiciones liberan el análogo de citidina sustancialmente en el estómago. También se proveen métodos para tratar enfermedades y trastornos que usan las formulaciones orales provistas en la presente.
EC2010010665A 2008-05-15 2010-12-07 Formulaciones orales de análogos de citidina y métodos para usar los mismos ECSP10010665A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
ECSP10010665A true ECSP10010665A (es) 2011-01-31

Family

ID=40941609

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010665A ECSP10010665A (es) 2008-05-15 2010-12-07 Formulaciones orales de análogos de citidina y métodos para usar los mismos

Country Status (34)

Country Link
US (12) US8846628B2 (es)
EP (6) EP4327888A3 (es)
JP (3) JP2011520880A (es)
KR (1) KR101633134B1 (es)
CN (3) CN102099018B (es)
AR (1) AR071808A1 (es)
AU (3) AU2009246926B2 (es)
BR (1) BRPI0912717A2 (es)
CA (3) CA3094590A1 (es)
CL (2) CL2009001170A1 (es)
CO (1) CO6300930A2 (es)
CR (1) CR11789A (es)
CY (3) CY1121350T1 (es)
DK (5) DK3692983T3 (es)
EC (1) ECSP10010665A (es)
ES (5) ES2712506T3 (es)
FI (1) FI3782612T3 (es)
HR (5) HRP20231439T1 (es)
HU (5) HUE047707T2 (es)
IL (2) IL209307A (es)
LT (5) LT3692983T (es)
MX (2) MX2010012470A (es)
MY (1) MY161593A (es)
NI (1) NI201000193A (es)
NZ (3) NZ623495A (es)
PE (2) PE20091971A1 (es)
PL (5) PL3692983T3 (es)
PT (5) PT2299984T (es)
RU (3) RU2476207C2 (es)
SG (1) SG193206A1 (es)
SI (5) SI3782612T1 (es)
TW (3) TWI522103B (es)
WO (1) WO2009139888A1 (es)
ZA (1) ZA201008229B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
EP4327888A3 (en) * 2008-05-15 2024-05-22 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) * 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
SG10201504590WA (en) * 2010-06-07 2015-07-30 Abraxis Bioscience Llc Combination Therapy Methods For Treating Proliferative Diseases
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
CN103619864A (zh) 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
US9125884B2 (en) * 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
HK1201733A1 (en) 2011-11-03 2015-09-11 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
WO2014083133A1 (en) * 2012-11-29 2014-06-05 Cellectis Sa Improved methods for producing mammalian pluripotent stem cell-derived endodermal cells
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US20150359810A1 (en) * 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
MX2017014987A (es) * 2015-05-22 2018-04-13 Novartis Ag Composiciones farmaceuticas.
CN108697698B (zh) * 2015-10-15 2021-12-03 阿吉奥斯制药公司 用于治疗恶性肿瘤的组合疗法
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US11376270B2 (en) 2015-12-03 2022-07-05 Epidestiny, Inc. Compositions containing decitabine, 5Azacytidine and tetrahydrouridine and uses thereof
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
EP3986404A1 (en) 2019-06-20 2022-04-27 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
EP4034082A4 (en) * 2019-09-25 2023-07-05 Aardvark Therapeutics Inc. Oral pharmaceutical immediate release composition and method of treatment for weight loss
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
EP4085902B1 (en) * 2019-12-31 2025-04-30 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115768432A (zh) 2020-04-23 2023-03-07 南方研究院 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
CN115989229A (zh) 2020-07-23 2023-04-18 南方研究院 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
WO2022112578A1 (en) * 2020-11-27 2022-06-02 Centre Leon Berard Ribosomal rnas 2'o-methylation as a novel source of biomarkers relevant for diagnosis, prognosis and therapy of cancers
US11858956B2 (en) 2020-12-18 2024-01-02 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
TW202539733A (zh) 2023-11-28 2025-10-16 法商賽諾菲公司 用於治療血液腫瘤病症之多功能自然殺手（ｎｋ）細胞接合物組合療法
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (es) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
DK0397042T3 (da) 1989-05-10 1995-10-02 Hoffmann La Roche Fremstilling af isoquinolinderivater
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
PT1027359E (pt) 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
CN1361694A (zh) 1999-07-16 2002-07-31 天藤制药株式会社 粘膜吸收甘草甜素制剂
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002098420A1 (en) 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
CA2526908A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
US20070190022A1 (en) * 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
KR101976003B1 (ko) 2005-02-18 2019-05-09 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en) 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2205073A4 (en) 2007-09-26 2013-03-06 Sinai School Medicine AZACYTIDINE ANALOGS AND USES THEREOF
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
EP4327888A3 (en) 2008-05-15 2024-05-22 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2324042B1 (en) 2008-08-06 2012-11-28 Sicor, Inc. Process for preparing azacytidine intermediate
ES2487525T3 (es) 2008-08-08 2014-08-21 Scinopharm Taiwan Ltd. Procedimiento para preparar nucleósidos de 5-azacitosina y sus derivados
RU2531948C2 (ru) 2008-11-22 2014-10-27 Дженентек, Инк. Антиангиогенная терапия, применяемая для лечения рака молочной железы
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
CN103619864A (zh) 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs

Also Published As

Publication number Publication date
US20250082661A1 (en) 2025-03-13
CY1122681T1 (el) 2020-10-14
WO2009139888A1 (en) 2009-11-19
CA2761582C (en) 2022-06-07
AU2015202884B2 (en) 2017-02-23
SI3782612T1 (sl) 2024-02-29
RU2765076C2 (ru) 2022-01-25
CN103479586A (zh) 2014-01-01
HRP20211398T1 (hr) 2021-12-10
US20230255996A1 (en) 2023-08-17
PT3782612T (pt) 2024-01-18
AR071808A1 (es) 2010-07-14
LT3692983T (lt) 2021-11-10
US20200101095A1 (en) 2020-04-02
CA3094580C (en) 2021-05-18
CO6300930A2 (es) 2011-07-21
DK3782612T3 (da) 2024-01-15
IL209307A0 (en) 2011-01-31
US20090286752A1 (en) 2009-11-19
CA3094580A1 (en) 2009-11-19
MX2010012470A (es) 2010-12-02
RU2476207C2 (ru) 2013-02-27
US8846628B2 (en) 2014-09-30
AU2013202665A1 (en) 2013-05-02
US10220050B2 (en) 2019-03-05
RU2012147739A (ru) 2014-05-20
HUE059635T2 (hu) 2022-12-28
KR20110015629A (ko) 2011-02-16
JP2015110575A (ja) 2015-06-18
CA2761582A1 (en) 2009-11-19
EP2695609A1 (en) 2014-02-12
HUE055911T2 (hu) 2021-12-28
US20230241086A1 (en) 2023-08-03
ZA201008229B (en) 2012-02-29
PL2299984T3 (pl) 2019-07-31
DK3692983T3 (da) 2021-09-20
SI2299984T1 (sl) 2019-04-30
PL3782611T3 (pl) 2022-11-07
US20180153916A1 (en) 2018-06-07
CN103479586B (zh) 2017-03-01
SI3692983T1 (sl) 2021-11-30
EP3692983B1 (en) 2021-08-11
US12053482B2 (en) 2024-08-06
HRP20200096T1 (hr) 2020-04-03
HRP20231439T1 (hr) 2024-03-01
EP2695609B1 (en) 2019-12-11
US11571436B2 (en) 2023-02-07
ES2927556T3 (es) 2022-11-08
EP2299984B1 (en) 2018-11-28
MX363023B (es) 2019-03-05
CN105535008A (zh) 2016-05-04
BRPI0912717A2 (pt) 2014-12-23
DK3782611T3 (da) 2022-09-05
EP4327888A3 (en) 2024-05-22
PE20091971A1 (es) 2010-01-15
PT2299984T (pt) 2019-02-25
ES2774226T3 (es) 2020-07-17
PT2695609T (pt) 2020-03-02
PL3692983T3 (pl) 2021-12-27
MY161593A (en) 2017-04-28
US20200316099A1 (en) 2020-10-08
HRP20221064T1 (hr) 2022-11-11
HUE047707T2 (hu) 2020-05-28
EP3782611B1 (en) 2022-07-06
RU2010151428A (ru) 2012-06-20
JP6105547B2 (ja) 2017-03-29
DK2695609T3 (da) 2020-02-10
EP2299984A1 (en) 2011-03-30
US20220079964A1 (en) 2022-03-17
ES2712506T3 (es) 2019-05-13
TWI522103B (zh) 2016-02-21
NZ602833A (en) 2014-04-30
TW201513869A (zh) 2015-04-16
LT2695609T (lt) 2020-02-10
KR101633134B1 (ko) 2016-06-23
SI2695609T1 (sl) 2020-03-31
CY1121350T1 (el) 2020-05-29
CA3094590A1 (en) 2009-11-19
TWI618538B (zh) 2018-03-21
HRP20190100T1 (hr) 2019-04-05
EP3782611A1 (en) 2021-02-24
AU2009246926B2 (en) 2014-06-26
JP6426778B2 (ja) 2018-11-21
AU2009246926A1 (en) 2009-11-19
IL238087B (en) 2019-01-31
NI201000193A (es) 2011-08-01
NZ589437A (en) 2012-11-30
HUE064677T2 (hu) 2024-04-28
HUE042825T2 (hu) 2019-07-29
RU2018109222A (ru) 2019-09-17
US20190231803A1 (en) 2019-08-01
LT2299984T (lt) 2019-03-25
PT3782611T (pt) 2022-11-18
CR11789A (es) 2011-02-21
EP3782612B1 (en) 2023-11-08
CN102099018B (zh) 2016-01-13
CY1124720T1 (el) 2022-07-22
CN102099018A (zh) 2011-06-15
IL209307A (en) 2016-02-29
RU2018109222A3 (es) 2021-07-02
TW201006478A (en) 2010-02-16
US20150056280A1 (en) 2015-02-26
ES2969144T3 (es) 2024-05-16
LT3782611T (lt) 2022-10-10
TW201729817A (zh) 2017-09-01
FI3782612T3 (fi) 2024-01-16
PL2695609T3 (pl) 2020-05-18
CL2009001170A1 (es) 2010-06-04
US20220105118A1 (en) 2022-04-07
PE20142440A1 (es) 2015-01-28
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
US10463683B2 (en) 2019-11-05
AU2015202884A1 (en) 2015-06-18
US10646503B2 (en) 2020-05-12
JP2017137326A (ja) 2017-08-10
ES2893785T3 (es) 2022-02-10
PT3692983T (pt) 2021-11-08
US20150374732A1 (en) 2015-12-31
SI3782611T1 (sl) 2022-10-28
LT3782612T (lt) 2023-12-27
EP3692983A1 (en) 2020-08-12
NZ623495A (en) 2015-08-28
JP2011520880A (ja) 2011-07-21
CL2013001097A1 (es) 2013-11-29
EP4327888A2 (en) 2024-02-28
AU2013202665B2 (en) 2015-06-25
DK2299984T3 (en) 2019-03-04
EP3782612A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
CO6300930A2 (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
ECSP10010489A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CO6400193A2 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
MX2020008616A (es) Rocio de fentanilo sublingual.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
ECSP10010015A (es) Inhibidores de proteasoma
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
ECSP11010834A (es) Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina
UY31922A (es) Compuestos
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
DOP2006000287A (es) Derivados de piperidina
NI201200196A (es) Agentes terapéuticos 976
UA101370C2 (ru) Пероральные составы, которые содержат аналоги цитидина, и способы их использования
CY1116836T1 (el) Μεθοδοι για την θεραπευτικη αγωγη της λιπωδους νοσου του ηπατος που περιλαμβανουν αναστολη της συνθεσης του γλυκοσφιγγολιπιδιου